ZBIO as reported
Zenas BioPharma, Inc. reported $10M of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.
$10M
Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied
- Net Income
- −$425M
Net Income · +161% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$210M
Free Cash Flow · +53% year on year · trailing twelve months to Q1 2026
- EPS
- −$9.10
EPS · −31% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $10M | n/a | Q4 2025 |
| Net Income | −$425M | +161% | Q1 2026 |
| EPS | −$9.10 | −31% | Q1 2026 |
| ROE | −113% | n/a | Q1 2026 |
| ROA | −69% | n/a | Q1 2026 |
| Free Cash Flow | −$210M | +53% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Zenas BioPharma, Inc. (ZBIO) - Revenue & ProfitRevenue & ProfitZenas BioPharma, Inc. (ZBIO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com